Daxxify® Surpasses 1 Million Vials Distributed in US Aesthetic Market

Revance Therapeutics has announced the distribution of more than 1 million vials of daxibotulinumtoxinA-lanm (Daxxify®) for aesthetic use in the United States, marking a notable milestone 3 years after the product received US Food and Drug Administration (FDA) approval.

According to a press release, Daxxify® is the only botulinum toxin formulation incorporating a proprietary peptide, and it is manufactured without human- or animal-derived components. The injectable neurotoxin is approved for the temporary improvement of moderate to severe glabellar lines and is positioned as an alternative to other botulinum toxin products.

According to the company, Daxxify’s clinical profile includes rapid onset and durable results, with some studies reporting efficacy lasting up to 6 months or longer. These attributes may support reduced treatment frequency, potentially aligning with patient preferences for longer intervals between treatments.

“Reaching the 1 million-vial mark represents an important milestone in the advancement of aesthetic medicine and of Daxxify®,” Revance chief scientific officer Conor Gallagher, PhD, said. “This achievement highlights the trust our provider partners place in our peptide-formulated neurotoxin and reflects the value they place in innovation that translates into true clinical outcomes. We are encouraged by the growing body of real-world experience, and we are actively continuing to expand the science and data supporting Daxxify®.”

Daxxify® received FDA approval for aesthetic use in 2022 and for therapeutic use in cervical dystonia in 2023.